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14 Abstract
15 Background: Annona muricata L. was identified as a popular medicinal plant in treatment regimens among cancer
16 patients in Jamaica by a previously conducted structured questionnaire. Ethnomedically used plant parts, were
17 examined in this study against human prostate cancer cells for the first time and mechanisms of action elucidated
18 for the most potent of them, along with the active phytochemical, annonacin.
19 Methods: Nine extracts of varying polarity from the leaves and bark of A. muricata were assessed initially for
20 cytotoxicity using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay on PC-3 prostate
21 cancer cells and the ethyl acetate bark (EAB) extract was identified as the most potent. EAB extract was then
22 standardized for annonacin content using High-performance Liquid Chromatography - Mass Spectrometry (HPLC-
23 MS) and shown to be effective against a second prostate cancer cell line (DU-145) also. The mode of cell death in
24 DU-145 cells were assessed via several apoptotic assays including induction of increased reactive oxygen species
25 (ROS) production, reduction of mitochondrial membrane potential, activation of caspases and annexin V
26 externalization combined with morphological observations using confocal microscopy. In addition, the potential to
27 prevent metastasis was examined via inhibition of cell migration, vascular endothelial growth factor (VEGF) and
28 angiogenesis using the chorioallantoic membrane assay (CAM).
29 Results: Annonacin and EAB extract displayed selective and potent cytotoxicity against the DU-145 prostate
30 carcinoma cells with IC50 values of 0.1 ± 0.07 μM and 55.501 ± 0.55 μg/mL respectively, without impacting RWPE-1
31 normal prostate cells, in stark contrast to chemotherapeutic docetaxel which lacked such selectivity. Docetaxel’s
32 impact on the cancerous DU-145 was improved by 50% when used in combination with EAB extract. Insignificant
33 levels of intracellular ROS content, depolarization of mitochondrial membrane, Caspase 3/7 activation, annexin V
34 content, along with stained morphological evaluations, pointed to a non-apoptotic mode of cell death. The extract
35 at 50 μg/mL deterred cell migration in the wound-healing assay, while inhibition of angiogenesis was displayed in
36 the CAM and VEGF inhibition assays for both EAB (100 μg /mL) and annonacin (0.5 μM).
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37 Conclusions: Taken together, the standardized EAB extract and annonacin appear to induce selective and potent
38 cell death via a necrotic pathway in DU-145 cells, while also preventing cell migration and angiogenesis, which
39 warrant further examinations for mechanistic insights and validity in-vivo.




43 Small molecular secondary metabolites found expressed in
44 plants have played a key, adaptive role aiding in their evolu-
45 tion from single cellular organisms coping in a harsh chem-
46 ical soup, to being multicellular, terrestrial organisms,
47 equipped to gain reproductive vantages or vade off over-
48 grazers and diseases [1]. These vastly diverse group of small
49 molecules that provide the plant with such advantages other
50 than their primary functions of respirations, have inspired
51 man-kind to experiment on plants over millennia for solu-
52 tions to their own health problems. Thus, the high reliance
53 on plant remedies by over 80% of the developing world for
54 primary care [2], similar to the 73% self-medicating rates
55 with herbs in Jamaica [3], provide evidence for the strong
56 belief in the healing properties resident in plants. The devel-
57 opment mean of approximately 32% of pharmaceuticals and
58 botanical mixtures derived directly from or inspired by
59 natural products over the past 39 years [4] for the treatment
60 or prevention of multiple health issues including cancer, dia-
61 betes and microbial infections, provide credence to such
62 beliefs.
63 Unsurprisingly plants have been utilized in the man-
64 agement of cancer since time immemorial in many trad-
65 itional medical systems and remain a major source for
66 bioprospecting [5], having inspired over 50% of cancer
67 drugs approved over the past four decades [4], including
68 vincristine, vinblastine, paclitaxel, camptothecin and
69 podophyllotoxin [6]. Jamaica has a wide array of self-
70 medicated herbs and medicinal plants in use against ill-
71 nesses [7], with some displaying anti-cancer properties.
72 Petiveria alliacea and key phytochemical, dibenzyl tri-
73 sulfide [8] and the Jamaican ball moss (Tillandsia recur-
74 vata L.) [9] exemplifies use in prostate cancer, among
75 other biodiversity with disparate cytotoxic properties
76 [10]. A recent survey among cancer patients in the coun-
77 try [11] helped identify common ethnomedical practices
78 in the island nation and Annona muricata L. emerged as
79 a popular ingredient, in line with findings emerging from
80 Indonesia, [12] and Trinidad [13].
81 Comprehensive ethnobotanical studies of the Annonaceae
82 family have been conducted in recent years [14] and the
83 therapeutic potential of Annona muricata, the most promin-
84 ent species of the Annonaceae family examined in the treat-
85 ment of insomnia, rheumatism, hypertension and various
86cancers [15]. Reports have emerged from Nigeria [16],
87Mexico [17] and the Philippines [15] for the therapeutic
88application of a decoction of the leaves to treat cancers of
89the prostate and stomach among others, while in Peru [18],
90infusions of the leaves are used for cancer treatment [15].
91Evaluating these reports highlight the fact that although leaf
92preparations have undergone some scrutiny, bark extracts
93have remained largely unexplored.
94The two major classes of phytochemicals found in A.
95muricata are flavonoids and acetogenins both of
96which are associated with a plethora of pharmaco-
97logical activities individually or synergistically in a
98wide array of plants [19–21]. Annonacin commonly
99occurs in various species of the Annonaceae family
100and is the major acetogenin of A. muricata [22]. Mul-
101tiple studies have demonstrated its ability to exert
102anti-tumor effects against endometrial, breast and skin
103cancer through cell cycle arrest and other cell signal-
104ing pathways [23–25]. There is mounting evidence to
105support the antitumor activity through apoptosis in-
106duction in numerous cancer cell lines such as colon
107and breast cancer [5]. This, along with cell cycle arrest
108at G1 phase are some of the well reported antitumor
109mechanisms of A. muricata leaf [26–30]. Though,
110many studies have shown mitochondrial mediated
111apoptosis, cell death can occur independently of mito-
112chondrial involvement without the generation of Re-
113active Oxygen Species (ROS) to trigger apoptosis, and
114full evaluations are required in each type of cancer
115cell.
116In this study we evaluated, the cytotoxic value of
117polar and non-polar leaf and bark extracts of A.
118muricata, the two most popularly used plant parts in
119ethnomedicine [11] on prostate cancer cells. With the
120aid of a panel of biochemical monitors, we demonstrate
121the usefulness of the most potent of those extracts,
122along with the key phytochemical annonacin, alone and
123in combination therapy with a standard chemothera-
124peutic drug, docetaxel. Their impact on prostate cells
125was independent of ROS, caspases activity and ap-
126peared to follow a necrotic pathway of cytotoxicity.
127Demonstrating strong anti-angiogenetic properties
128these natural products warrant future in-depth scrutiny
129on in-vivo prostate cancer models.
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130 Methods
131 Plant material
132 Aerial parts (leaf and bark) of Annona muricata were
133 collected in August 2017 from the Botanical Gardens at
134 the University of the West Indies (U.W.I), Mona,
135 Jamaica. A. muricata, which grows wildly in Jamaica is
136 not an endangered species, hence no special governmen-
137 tal permission was required for collection. Voucher
138 specimens were deposited at the Herbarium in the
139 Department of Life Sciences, U.W.I., Mona with Acces-
140 sion Numbers 36,362 and 36,363, following authentica-
141 tion by herbarium curator, Mr. Patrick Lewis.
142 Preparation of extracts
143 The leaves and bark of A. muricata were collected,
144 cleaned, dried at room temperature and pulverized into
145 powder. 5 g of leaf and bark separately or 2.5 g leaf and
146 2.5 g bark combined were then sequentially extracted
147 with hexane, ethyl acetate and ethanol (200mL each) for
148 3 days at room temperature. Three extracts per solvent
149 (hexane, ethyl acetate and ethanol) were prepared using
150 the leaf, bark and leaf:bark combination in a 1:1 ratio to-
151 taling nine extracts of varying polarity. The resulting
152 suspension from solvent extract was filtered through
153 type 2 Whatman filter paper and the filtrate evaporated
154 to dryness using a rotary evaporator at low temperature
155 [28]. The extracts obtained from each solvent were
156 weighed, labeled and stored at − 20 °C in sealed tubes
157 until further use.
158 Cell culture
159 PC-3 and DU-145 human prostate carcinoma cells
160 and RWPE-1 normal prostate epithelial cells ob-
161 tained from American Type Cell Collection (ATCC,
162 Manassas, VA, USA) were used for the cytotoxicity
163 determination in the study. PC-3 cells were main-
164 tained in Kaighn’s modification of Ham’s F-12
165 medium (F-12 K) and DU-145 cells were maintained
166 in ATCC formulated Eagle’s Minimum Essential
167 Medium (EMEM) supplemented with 10% fetal
168 bovine serum (FBS) while RWPE-1 cells were main-
169 tained in Keratinocyte Serum Free Medium supple-
170 mented with human recombinant epidermal growth
171 factor and bovine pituitary extract. All cell lines
172 were incubated in a humidified atmosphere with 5%
173 carbon dioxide in the air at 37 °C until 90% conflu-
174 ence after which they were harvested for the viability
175 experiments.
176 Cell viability assay
177 The MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
178 tetrazolium bromide) was used to evaluate cell viability. An
179 optimized cell concentration 15,000 cells/well were seeded in
180 96-well plates and incubated for 24 h. Cells were
181subsequently treated with extracts, annonacin, docetaxel and
182a combination of EAB extract and docetaxel at different con-
183centrations ranging from 50 to 100 μg/mL extract and
1840.0001–0.0016 μg/mL for docetaxel and incubated for 72 h,
185after which the MTT solution was added and incubated for
186another 4 h at 37 °C then medium aspirated and the crystals
187formed solubilized with the addition of 100 μL dimethyl sulf-
188oxide (DMSO) to each well. Finally, the resulting absorbance
189was measured at 570 nm using a microplate reader and the
190percentage of cell viability calculated as a ratio of untreated
191cells in vehicle control (1% DMSO). The experiments were
192performed in triplicate and the results expressed as the
193mean ± standard error of the mean [31, 32].
194Standardization of extract using HPLC-MS
1955.7 mg of the ethyl acetate extract was dissolved in 57 μL
196methanol and analyzed by HPLC-MS (Velos-Pro,
197Thermo Fisher Scientific); Phenomenex C18 column:
198150 × 3mm, 3 μm particle size (method:0–1 min = iso-
199cratic gradient 10%methonol, 90% H2O; 1–18min = lin-
200ear gradient 30% methanol, 70% H2O to 78% methanol,
20122% H2O; 18–20 min = 78% methanol, 22% H20 to 100%
202methanol) alongside standard of pure annonacin. Con-
203centrations were estimated from the peak area of the
204corresponding molecular ion peak ([M +H]+; m/z
205597.60) in positive electron spray ionization mode, using
206known concentrations of annonacin standard for calibra-
207tion, and accounting for dilution in 80% methanol [33].
2081H NMR spectrum of pure annonacin was analyzed
209using a 400MHz NMR Avance spectrophotometer to
210authenticate it.
211Reactive oxygen species assay
212The generation of reactive oxygen species (ROS) is often
213associated with chemotherapeutic and other non-
214surgical interventions in cancer, as a means of triggering
215cell death. Often the intracellular generation of ROS is
216indicative of early induction of apoptosis [34]. Since
217ROS generations were previously observed for A.
218muricata leaf and twig extracts in HL-60 leukemia cells
219[35], we evaluated such potential by EAB extract and
220annonacin on DU-145 cells. Intracellular ROS gener-
221ation was determined using the single reagent 2′,7′–
222dichlorofluorescein diacetate (DCFDA). This is a cell
223permeant, fluorogenic dye which can be oxidized to
224DFC (2′,7′– dichlorofluorescein) which is the fluores-
225cent product, detected by a spectrofluorometer used to
226measure hydroxyl, peroxyl and other reactive oxygen
227species (ROS) activity within the cell [35]. DU-145 cells
228were treated with the EAB extract, annonacin and
2292.5 μM hydrogen peroxide (H2O2) as positive control for
23072 h. After incubation, the media was removed, cells
231were washed with Phosphate-buffered saline (PBS) then
232stained with 100 μL DCFDA and incubated for another
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233 30 mins in the dark at 37 °C. After which the fluores-
234 cence intensity was subsequently measured at 485 nm
235 excitation and 535 nm emission using a microplate
236 reader.
237 Mitochondrial membrane potential using the JC-10 assay
238 The mitochondria play an important role in apoptosis
239 detection and induction of cell death [36]. The change
240 in mitochondrial membrane potential (MMP) was mea-
241 sured using the JC-10 assay kit (Sigma-Aldrich, USA)
242 according to vendor’s instructions. This uses a dual
243 emission fluorescent dye capable of entering the mito-
244 chondria and emits either red or green fluorescence
245 depending on the state of the mitochondrial membrane.
246 Red fluorescence is seen in normal polarized mitochon-
247 dria while a green fluorescence is obtained when the
248 mitochondrial membrane potential decreases and the
249 membrane is depolarized causing the dye to diffuse into
250 the cytoplasm of the cell. Treated DU-145 cells (with
251 docetaxel, varying concentrations of EAB, annonacin,
252 control and 10 μM of H2O2) were incubated in 96-well
253 plates for 72 h. After incubation, the media was re-
254 moved, cells were washed with PBS then stained with
255 50 μL/well of the JC-10 dye loading solution. The plate
256 was then incubated for 50 mins in a 37 °C incubator pro-
257 tected from light after which 50 μL/well of assay buffer B
258 was added, then fluorescence intensity subsequently read
259 at excitation/emission wavelengths of 490/525 nm and
260 540/590 nm [37]. Results are recorded as a ratio of red
261 to green fluorescence.
262 Human Annexin V assay
263 During apoptosis, the cell membrane is altered and
264 Phosphatydylserine (PS) located in the membrane leaf-
265 lets become exposed at the cell surface and allow for
266 binding of annexin V. Total annexin V in treated DU-
267 145 prostate cancer cells was quantitatively measured
268 with the Human annexin V Platinum ELISA kit
269 (Affymetrix, eBioscience, Vienna, Austria) by comparing
270 to the standard provided in kit following the vendor’s kit
271 manual. Briefly, 50 μL of treated cell supernatant in trip-
272 licates was used for annexin V determination. The assay
273 was conducted at room temperature and results moni-
274 tored at 620 nm [38].
275 Caspase 3/7 assay
276 Manufactures’ instructions were followed for CellEvent®
277 Caspase-3/7 Green reagent allowing detection of Cas-
278 pase 3 activity. Briefly, treated DU-145 cells were
279 incubated for 24 h with 0.6 μg/mL annonacin, (50 and
280 100 μg/mL) EAB extract and 10 μM of H2O2 as positive
281 control in 96-well plates at a concentration of 15,000
282 cells/well. After incubation 4 μM Caspase-3/7 Green
283 Detection Reagent was added to each well and incubated
284for 30mins. The results were analyzed by a fluorescence
285microplate reader at 503 nm/530 nm excitation/emission
286[39, 40].
287Ethidium bromide and Acridine Orange staining
288Cells were seeded into 6-well plates lined with coverslips
289at a concentration of 250,000 cells/well. Confluent cells
290were treated with various concentrations of extract and
291compound and incubated for 72 h. After incubation, the
292cells were subsequently washed with PBS and then
293treated with a dye mixture containing ethidium bromide
294and acridine orange (1:1, 100 μg/mL) for 15 min covered
295with foil. After 15 mins the stain was removed, and the
296cells rinsed with PBS. 1 ml of paraformaldehyde was
297added to the cells for 15 mins to fix the stained cells on
298the slides. After removing the paraformaldehyde, the
299coverslips were removed and mounted on slides viewed
300under confocal microscopy [41].
301Cell migration assay
302The more metastatic prostate cancer cell line (PC-3) was
303used to assess the anti-metastatic potential of the EAB
304extract. PC-3 cells were seeded into 6-well plates at a
305concentration of 250,000 cells/well. Confluent cells were
306scratched using a sterile 200-μl pipette tip and washed
307twice with PBS to remove detached cells. The image of
308cells in each well was captured at time 0 h. Cells were
309treated with various concentrations of extract and incu-
310bated for 24 h at 37 °C with 5% carbon dioxide in the at-
311mosphere. After incubation, cells were washed with PBS
312to remove cell debris [28, 42]. Images were subsequently
313captured after incubation using an Amscope digital eye-
314piece microscope camera attached to an inverted micro-
315scope. Statistical analysis using GraphPad software and
316results expressed as percentage cell migration.
317Chicken chorioallantoic membrane - CAM assay
318Three eggs per sample (in triplicates) were obtained
319from a local hatchery in Bloemfontein, South Africa and
320incubated for 8 days at 37 °C with 60% humidity. Egg
321shells were sterilized with 70% ethanol and a 1 cm2 win-
322dow on the air space end was cut opened on the 8th day
323to expose the blood vessels. A 1 cm2 sterile Whatman
324filter paper shocked with the compound, extract, Tinza-
325parin (positive control) and L-arginine (negative control)
326was placed on the surface of the growing CAM vessels.
327The eggs were then labelled and re-sealed with sterile
328adhesive tape in a laminar flow hood and incubated for
329another 3 days. On day 11, the CAMs were reopened in
330sterile petri dishes, photographed and blood vessels in
331each CAM were counted. The results were presented as
332the angiogenic index for each sample [43, 44].
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333 VEGF inhibition assay
334 The extracellular vascular endothelial growth factor
335 (VEGF) levels were assayed using the supernatant of
336 earlier treated DU-145 cells [43]. The cells were seeded
337 in a 48-well plate at a concentration of 50,000 cells per
338 well. To influence the cell growth and VEGF production,
339 0.01 mg/ml of insulin was supplemented in the culture
340 medium. After 24 h incubation, cells were treated with
341 extract and test compound and incubated for 72 h after
342 which plates were centrifuged at 5000 g for 10 min and
343 the supernatant collected for VEGF estimation. Total
344 VEGF content in cultured supernatants was estimated
345 following the instructions of Human VEGF ELISA kit
346 (ThermoFisher Scientific).
347 Statistical analysis
348 The results were expressed as the mean ± standard
349 errors of the mean. Assays were conducted in three indi-
350 vidual experiments, each performed in triplicates. IC50
351 values were determined using nonlinear regression ana-
352 lysis on Sigma Plot (version 10.0) software. All other
353 statistical analyses were performed with GraphPad Prism
354 8.0 (USA). The overall effects of plant part, solvent type
355 and the interaction of both on cell viability were deter-
356 mined using two-way ANOVA followed by Tukey’s
357 multiple comparisons test to check for significant dif-
358 ferences between the data. One-way analysis of variance
359 (ANOVA) followed by Tukey’s multiple comparisons
360 post hoc test was used to compare treated cells with
361 the control. Significant differences were reported with
362 *** indicating a p-value < 0.0001, ** indicating a p-value
363 < 0.001 and * indicating a p-value < 0.05.
364 Results
365 Selective cytotoxic effect of A. muricata extracts on PC-3
366 prostate cancer cells and RWPE-1 normal prostate cells
367 Nine extracts of varying polarity including three
368 extracts per solvent (hexane, ethyl acetate and etha-
369 nol) prepared using the leaf, bark and leaf:bark com-
370 bination in a 1:1 ratio were analyzed for their
371 cytotoxic potential. This experiment utilized the most
372 commonly used parts of the plant in ethnomedical
373 practices. All such extracts prepared were subse-
374 quently screened at a concentration of 100 μg/mL
375 against cancerous (PC-3) and normal (RWPE-1) pros-
376 tate cell lines and results depicted in Fig.F1 1. Inducing
377 the largest impact (30% cell viability) on the cancer-
378 ous PC-3 cells, the ethyl acetate extract of the bark
379 was identified as the most potent and selective, with
380 negligible impact (> 90% cell viability) on the normal
381 cells. It is noteworthy that all examined extracts of
382 this plant elicited low cytotoxicity on normal cells.
383Standardization of ethyl acetate bark extract
384Having identified the ethyl acetate extract of the bark
385(EAB) as the most potent, the presence of the key phyto-
386chemical, annonacin, was identified and quantified in
387this extract using HPLC-MS (Fig. F22). The level of anno-
388nacin was < 100 ppm when compared to its standard.
389After filtering for a molecular weight of 597.5 (+/− 1.5)
390in positive mode, accounting for the added ion to anno-
391nacin molecular weight, and compared to the standard it
392was determined that annonacin is identifiable with a
393retention time, leaving the column at, 23.07 min with a
394molecular weight of 597.60.
395Improved cytotoxicity of chemotherapeutic drug,
396docetaxel in combination with standardized EAB extract
397To ensure that the observed cytotoxicity with PC3 in
398Fig. 1 was not cell line dependent, we examined the
399effect of EAB extract and annonacin on DU-145 cells
400also, a cell line derived from brain metastasis of human
401prostate cancer [45, 46]. Dose dependent inhibitions of
402the growth of DU-145 were observed after 72 h incuba-
403tions (Fig. F33) and the IC50 values obtained for the extract
404(55.5 ± 0.55 μg/mL) and annonacin (0.079 ± 0.07 μg/mL
405or 0.1 μM), were compared to that of docetaxel
406(0.0004 ± 1.59X10− 5 μg/mL or 0.05 nM), a standard che-
407motherapeutic drug as shown in Table T11. Combining do-
408cetaxel with EAB extract induced an even greater impact
409on cell viability (Fig. 3d), reducing the IC50 of the former
410to 0.0002 μg/mL within a 95% confidence interval. A
411likely synergistic interaction underlies this improvement
412of docetaxel impact in the presence of the extract and
413we recommend future studies for a full understanding of
414this hypothesis. Having observed that the EAB extract is
415effective in reducing the cell viability of a second type of
416prostate cancer cell line, we undertook further work on
417the extract to gain mechanistic insights using DU-145
418cells. Since DU145 models a moderately metastatic pros-
419tate cancer as opposed to grade IV adenocarcinoma PC3
420cells with high metastatic potential, we selected the
421DU145 cell line for mechanistic study with suitability for
422studying treatment interventions in the early stages.
423Additionally, PC3 is suspect of carrying co-regulators for
424tumor suppression, which could complicate mechanistic
425studies, weighing into our decision to work with DU145
426cells for this study.
427EAB extract and annonacin does not elicit ROS generation
428in DU-145 cells
429Our results using the fluorogenic probe, 2, 7-
430dichlorofluorescin diacetate (H2DCFDA) which oxidizes
431to its highly fluorescent form dichlorofluorescein (DCF)
432in the presence of ROS, indicate that neither the A.
433muricata extract nor annonacin triggered significant in-
434creases in levels of intracellular ROS in prostate cancer
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435 cells. When compared to the untreated control, there
436 was no difference in the percent ROS obtained as shown
437 in Fig.F4 4, in contrast to a 2.5 μM solution of hydrogen
438 peroxide which elicited a three-fold increase in oxidative
439 capacity, while 10 μM hydrogen peroxide elicited a
440 nineteen fold increase (data not displayed).
441Measurement of mitochondrial membrane potential by
442JC-10 assay
443Cells treated with annonacin and EAB extract displayed a
444ratio comparative to the control healthy cells, indicating
445that the cytotoxic effect of A. muricata bark extract in
446prostate cancer cell does not involve the depolarization of
f2:1Q4 Fig. 2 HPLC-MS chromatogram of the standardized EAB extract showing annonacin. Filtered positive mode output (597.5 (+/− 1.5) from Velos
f2:2 pro representing the annonacin (inset) abundance in bark of Annona muricata. Annonacin is identified at 23.07 min
f2:3
f1:1 Fig. 1 A. muricata L. leaf and bark extracts display selective anti-proliferative activity on prostate cancer cells. PC-3 prostate cancer cell line (a) and
f1:2 RWPE-1 normal prostate cell line (b) were treated for 72 h with 100 μg/mL extracts of hexane, ethanol and ethyl acetate of leaf, bark alone and
f1:3 leaf:bark in 1:1 ratio. Cell viability was calculated as a percentage of solvent control (1% each solvent as control for each type of extract) and
f1:4 results are represented as mean ± SEM (n = 3). For different extracts with the same plant part, # represents statistically significant differences (p <
f1:5 0.05, two-way ANOVA). ‘ns’ represents no statistical significance
f1:6
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447 mitochondrial membrane (Fig.F5 5). In contrast, docetaxel
448 (known to impart anti-cancer activity via apoptotic path-
449 way) displayed significantly lower ratio of healthy red cells
450 in comparison to the damaged green cells (69%, red:green
451 ratio) in comparison to the untreated cells. Similarly, a
452 10 μM solution of hydrogen peroxide solution was able to
453 depolarize the mitochondrial membrane resulting in a sig-
454 nificantly reduced (35%) healthy cell content ratio in com-
455 parison to the control.
456Human Annexin V externalization confirms lowered
457apoptotic body formation
458To further confirm the absence of an apoptotic pathway,
459the levels of annexin V present in the cell membrane of
460treated DU-145 prostate cancer cells were quantitatively
461determined using the Human annexin V ELISA kit and
462compared to the provided standard, annexin V in buff-
463ered protein base. Results indicate that treated DU-145
464cells displayed low levels of annexin V when treated with
465annonacin as evident in Fig. F66, with anomalous behavior
466at 30 μg/mL and 50 μg/mL. However, statistical analysis
467showed there was no significant difference between all
468tested concentrations in comparison to the control.
469Whether there is some combination of apoptotic bodies
470being formed at these low concentrations followed by
471other forms of cell death, remains to be fully explored,
472but certainly the Fig. 6 indicates that between the range
473of 10-200 μg/mL annexin V levels stayed fairly uniform.
474Similarly, the levels of annexin V detected when cells
475were treated with annonacin is uniformly low as well.
f3:1 Fig. 3 EAB extract and annonacin display dose dependent impact on cell viability of DU-145 cells. Antiproliferative activity of (a) annonacin, (b)
f3:2 ethyl acetate extract of A. muricata bark (EAB), (c) docetaxel and (d) docetaxel in combination with 100 μg/ml EAB extract against DU-145
f3:3 prostate cancer cells determined by MTT assay after 72 h incubation with varying concentrations of each sample. Results are means ± SEM of
f3:4 triplicates in three independent experiments and the percentage of cell viability was calculated as a percentage of solvent control (1% DMSO). A
f3:5 dose dependent decrease in cell viability was observed with all test samples and combining docetaxel with the EAB extract reduced the
f3:6 observed IC50
f3:7
t1:1Q5 Table 1 IC50 values for the extract, annonacin and docetaxel on
t1:2 cancerous DU-145 cells and normal RWPE-1 cells, after 72 h
t1:3 Treatment Cell lines, IC50 value (μg/mL)
t1:4 DU-145 RWPE-1
t1:5 EAB extract 55.501 ± 0.55 > 300 *
t1:6 Annonacin 0.0793 ± 0.07 > 0.48 *
t1:7 Docetaxel 0.0004 ± 1.59 0.0004 α
t1:8 Results are expressed as mean ± SEM of three independent experiments. *
t1:9 represents the highest concentration tested where IC50 value was not
t1:10 determined. α- IC50 value obtained from Karanika et al. [47]
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476 Measurement of Caspase-3/7 activity
477 The activation of caspase-3 and caspase-7 which are
478 major players in the caspase cascade signaling apoptotic
479 cell death were evaluated to further characterize the
480 cytotoxicity induced by EAB and annonacin. As seen in
481 Fig.F7 7, neither annonacin nor the ethyl acetate extract of
482 A. muricata bark increased caspase-3/7 activity when
483 compared to untreated cells, suggesting a caspase inde-
484 pendent cell death. On the other hand, an increase in
485 caspase-3/7 activation was observed in cells treated with
486 a 10 μM solution of hydrogen peroxide - a widely used
487 apoptosis inducer [48].
488 Acridine Orange/ Ethidium bromide staining confirm
489 morphological changes
490 The images obtained after double staining treated cells
491 with acridine orange and ethidium bromide following a
492 72-h exposure to EAB extract and annonacin revealed
493 morphological changes which permits qualitative detec-
494 tions of modes of cell death. In Fig.F8 8 cells in the control
495 group appeared normal on confocal microscopy images
496 exhibiting bright green fluorescence signals from the
497 nuclei, suggesting the uptake of acridine orange stain
498 [49]. In the treatment groups, majority of the cells emit-
499 ted orange to red fluorescence signaling the uptake of
500ethidium bromide stain through damaged cell mem-
501branes. The nuclei of the cells were also characteristic-
502ally uniform depicting necrotic pathway, as they did not
503display visible apoptotic characteristics such as fragmen-
504tation of the nuclei or formation of apoptotic bodies.
505Inhibitory effect of EAB extract on the migration of
506prostate cancer cells
507In order assess A muricata’s effect on endothelial cell
508migration, a visual depiction was garnered using an in-
509vitro wound healing assay on highly metastatic PC-3
510prostate cancer cells as shown in Fig. F99. Both 50 μg/ml
511and 100 μg/ml of EAB extracts maintained a significant
512clearing of the denuded area created by the scratch on
513the monolayer of cells, in comparison to the ethyl acet-
514ate (solvent) treated and untreated controls after 24 h.
515Treatment yielded less than 20% of cell migration rates
516compared to the control groups seen to promote wound
517healing and cell migration for return of cell-cell contact.
f4:1 Fig. 4 EAB extract and annonacin yield no impact on intracellular
f4:2 Reactive Oxygen species (ROS). Intracellular ROS generated in DU-
f4:3 145 cells treated with 2.5 μM H2O2 (positive control), extract and
f4:4 annonacin relative to untreated cells (control) were assessed after
f4:5 72 h using the fluorescent probe DCF-DA. EAB extract and
f4:6 annonacin showed no impact on ROS generation. Data are means ±
f4:7 SEM of triplicates in three independent experiments. Statistical
f4:8 significance indicated by *** (one-way ANOVA, P < 0.0001)
f4:9
f5:1Fig. 5 EAB extract and annonacin does not alter the mitochondrial
f5:2membrane potential (MMP) in DU-145 cells. Quantitative evaluation
f5:3of the effects of annonacin and EAB extract on MMP in DU-145 cells
f5:4after 72 h was carried out using JC-10 Fluorescence dye computed
f5:5relative to untreated cells (control). Cell were treated with 10 μM
f5:6H2O2 and 2 nM docetaxel as positive control as docetaxel disrupts
f5:7MMP. EAB extract and annonacin displayed healthy cell content of
f5:8near 100% similar to the control, while those treated with docetaxel
f5:9yielded 69% healthy cell and hydrogen peroxide displayed 39%
f5:10healthy cell ratio, as measured by the healthy (red) cell count in
f5:11comparison to the damaged (green) cells. . Data are means ± SEM
f5:12of triplicates in three independent experiments. Statistical
f5:13significance indicated by *** (one-way ANOVA, P < 0.0001)
f5:14
Foster et al. BMC Complementary Medicine and Therapies _#####################_ Page 8 of 15
518 Quantification of angiogenic index induced by annonacin
519 and EAB extract via the CAM assay
520 Further evaluations on the A. muricata extract on angio-
521 genesis and tumor invasion was garnered by an assess-
522 ment using the high vascularized CAM assay. The EAB
523 extract at 60 μg/ml and 100 μg/ml inhibited the forma-
524 tion of new blood vessels in the CAM with an angio-
525 genic index of 35 and 23 respectively when compared to
526 the negative control L-Arginine, angiogenic index 53.
527 The suppression of angiogenesis shown by the com-
528 pound annonacin was similar to that observed for the
529 positive control tinzaparin (angiogenic index, 14). Anno-
530 nacin at 7 μg/ml (11.7 μM) had the lowest angiogenic
531 index of 19 amongst the tested samples when compared
532 to the positive control Tinzaparin as well as the negative
533 control L-Arginine as represented in Fig.F10 10 which
534 shows less defined capillaries in images 3–5 similar to
535 image 2 (positive control) in comparison to image 1 with
536 well-developed capillaries. These results highlight their
537 antiangiogenic potential which might prove beneficial in
538 preventing cancer metastasis.
539 VEGF inhibition induced by annonacin and EAB extract
540 To further evaluate the impact on angiogenesis, effect
541 on a potent angiogenetic factor, Vascular endothelial
542growth factor (VEGF) elicited by the natural extracts
543were quantified. All tested concentrations of the EAB
544extract significantly reduced the levels of VEGF in the
545cell in comparison to the control. However, 200 μg/mL
546of the extract, had the highest inhibition against the
547extracellular VEGF level and was significantly lower
548when compared between the groups (Fig. F1111).
549Annonacin at a concentration of 0.6 μg/mL (1 μM) was
550also found to reduce extracellular VEGF level when
551compared to the untreated control (media).
552Discussion
553Recognizing the value of ethnomedicine in the search
554for novel solutions, this investigation evaluated extracts
555of Annona muricata, which are employed by 52% of
556prostate cancer patients in Jamaica as home remedies
557[11], for impact against prostate cancer cells. The leaves
558and bark of this popular fruit tree are prepared as decoc-
559tions and infusions, and thus following evaluations of
560nine extracts of varying polarity, the ethyl acetate extract
561of the bark was deemed the most potent. It was there-
562fore standardized for annonacin content and evaluated
563for impact on prostate cancerous and normal cells
564followed by likely mechanism inducing such impact.
f6:1 Fig. 6 EAB extract and annonacin generates low annexin V content. Figure displays the concentrations of annexin V detected in DU-145 cells
f6:2 treated with varying concentrations of EAB extract and annonacin for 72 h calculated based on the standard curve generated. Data are expressed
f6:3 as means ± SEM of triplicate values and no statistically significant differences (indicated by ‘ns’) were observed from corresponding controls (one-
f6:4 way ANOVA), albeit the somewhat varying patterns displayed
f6:5
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569A. muricata is reportedly one of the most commonly
570used plants as complementary and alternative treatment
571by cancer patients in various cultures [11, 13, 50] and
572often used concomitantly with prescription medicines in
573patients undergoing chemotherapy [51, 52]. Interest-
574ingly, as Fig. 3 depicts, a possible synergistic interaction
575renders the EAB extract docetaxel combination signifi-
576cantly more effective than the pharmaceutical alone.
577Combined with the fact that annonacin and A. muri-
578cata extracts imparted highly selective cytotoxicity on
579cancerous cells in comparison to normal cells, stands it
580apart from pharmaceutical treatment alone. The potent
581IC50 value of 55 μg/ml for EAB extract against the can-
582cerous cells dwarfs in comparison to its IC50 for the
583normal prostate cells (> 300 μg/ml), similar to the 6-
584fold increase in IC50 of annonacin on normal cells
585(Table 1), while the impact of docetaxel stands in stark
586contrast invoking comparable toxicity on both normal
587and cancerous cells [47].
588Results garnered from Figs. 4 and 5 in this study, indi-
589cate that neither the extract nor annonacin induced cell
590death with an increasing ROS content or damage to the
591mitochondrial membrane. Cell deaths were observed
592without the activation of caspases (Fig. 7), a key require-
593ment used to confirm the induction of apoptosis in can-
594cer cells [53]. High doses of ROS can cause an
595irreversible loss of mitochondrial membrane potential in
596cells leading to the release of cytochrome c from the
597mitochondria and subsequent signaling of executioner
598caspases resulting in programmed cell death via apop-
599tosis pathway [34, 54]. Most pathways of programmed
600cell death involve regulation by the mitochondria but
601there are instances where cell death is controlled in the
602plasma membrane by its many receptors responsible for
603death signaling such as tumor necrosis factor and Fas
604[55]. Studies have demonstrated the potential of A.
605muricata extract to inhibit TNF-α [56]. The results of
606the annexin V binding assay in Fig. 6 illustrates that
f7:1 Fig. 7 Neither EAB extract nor annonacin increases caspase 3/7
f7:2 activity. Relative fluorescence expression of caspase-3/7 activity in
f7:3 DU-145 cells treated for 24 h with annonacin and ethyl acetate
f7:4 extract of A. muricata were detected using the fluorescence caspase-
f7:5 3/7 green reagent using untreated cells as control while 10 μM H2O2
f7:6 was used as positive control. No caspase-3/7 was detected when
f7:7 cells were treated with EAB extract and annonacin as expressed in
f7:8 fold higher than control activity. Data are expressed as means ± SEM
f7:9 of triplicate values. Data subjected to analysis using one-way
f7:10 ANOVA. ** indicates statistically significant difference from
f7:11 corresponding untreated control (P < 0.001)
f7:12
f8:1 Fig. 8 Confocal microscopy images of acridine orange/ethidium bromide double stained DU-145 cells reveals necrotic pathway in the presence
f8:2 of EAB and annonacin treatment. Treatment with (b) 50 μg/mL EAB extract and (c) 0.6 μg/mL annonacin for 72 h compared to (a) untreated cells
f8:3 as control reveal necrotic cells (red in appearance, red arrow) in annonacin and EAB treatment groups, in comparison to viable healthy cells as
f8:4 stained uniformly green (blue arrow) in (A) in the control group. Magnification 10 ×
f8:5
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607 there was some amount of phosphatidylserine exposure
608 detected by increase in annexin V concentration around
609 the IC50 which was not observed at higher concentra-
610 tions of the extract. Although externalization of phos-
611 phatidylserine is characteristic of apoptotic cells, no
612 significant increase in its content was observed and it
613 has been shown where phosphatidylserine can be
614 detected in early primary necrosis [57]. Other forms of
615 programmed cell death include necrosis-like cell death
616 characterized by the absence of both chromatin conden-
617 sation and caspase activation [58].
618 Engagement of necrosis-like form of cell death was
619 further suspected from the morphological observa-
620 tions using fluorescence microscopy following acridine
621 orange/ethidium bromide staining (Fig. 8). Both ex-
622 tract and phytochemical altered the cellular morph-
623 ology of the cells, exhibiting typical necrotic
624 characteristics with the absence of chromatin conden-
625 sation. Although some forms of apoptosis cannot be
626 totally ruled out. A. muricata has been shown to
627 induce necrosis in pancreatic cancer cells via the
628 inhibition of cellular metabolism [59], typical also of
629 some other natural products [4]. Necrosis can occur
630via an organized process resulting from a signaling
631cascade involving RIP kinase which is then termed
632necroptosis as some of the biochemical markers of
633this process are similar to apoptosis [53, 60]. The
634cross talk between apoptosis and necroptosis involv-
635ing numerous other pathways provides an opportunity
636for therapeutic development that can selectively target
637both or certain desired avenues [61]. Although apop-
638tosis is the cell’s preferred form of cell death, many
639tumors find effective ways for its evasion, leading to
640chemoresistance and tumor survival. Thus, therapies
641capable of activating non-apoptotic pathways poten-
642tially provide manipulation of cell deaths which would
643enhance their chemotherapeutic potential, should
644such resistance be developed. Whether or not the
645consumption of these natural products illicit an im-
646mune response as a result of resistance to apoptosis,
647and whether chronic inflammations is a result, are
648concerns worthy of future investigations using in-vivo
649models.
650The EAB extract proved able to inhibit motility in the
651highly metastatic PC3 cell line preventing the wound
652healing process as demonstrated by the cell migration
f9:1 Fig. 9 EAB extract significantly reduces cell migration. EAB extract at 100 μg/ml (d) and 50 μg/ml (c) inhibited migration of highly metastatic
f9:2 prostate cancer cells PC-3 cells compared to untreated control (a) and cells treated with solvent ethyl acetate (b). Cells were seeded into 6-well
f9:3 plates for 24 h after which each well was scratched at image captured at 0 h, treated and incubated for another 24 h where images were
f9:4 subsequently captured to demonstrate the extent of migration. The maintenance of a larger denude (visually) in the EAB treated groups indicate
f9:5 the lowered levels of cell migration (quantitated). Statistical significance indicated by ** indicating a p-value < 0.001 (one-way ANOVA)
f9:6
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f10:1 Fig. 10 Suppression of angiogenesis by EAB extract and annonacin. Representative results of the CAM assay displaying (a) angiogenic index
f10:2 obtained from each treatment and (b) images of the treated eggs opened on day 11. The images represent the following treatments 1: L-
f10:3 Arginine, 2: Tinzaparin (20 μg/mL), 3:EAB extract (60 μg/mL), 4:EAB extract (100 μg/mL), 5: Annonacin (7 μg/mL) and a summary of the angiogenic
f10:4 index obtained from each treatment. The results indicate a lowered angiogenesis potential in the presence of EAB and annonacin
f10:5
f11:1 Fig. 11 VEGF levels are significantly decreased in the presence of EAB extract and annonacin. DU-145 cultured supernatants obtained after 72 h treatment
f11:2 with various concentrations of EAB extract and annonacin are displayed. . Results are expressed as means ± SEM of triplicate values. * indicates statistically
f11:3 significant difference of all samples from corresponding control while a denotes significance between the groups (one-way ANOVA, P<0.05)
f11:4
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653 assay in Fig. 9, in addition to the significant inhibition of
654 extracellular VEGF in Fig. 11. The EAB extract and
655 annonacin also displayed potential in inhibiting the for-
656 mation of new blood vessels in the CAM (Fig. 10). The
657 ability of the tested extracts and annonacin to inhibit
658 extracellular VEGF levels and blood vessel formation ad-
659 duce to the probable potential of the samples to inhibit
660 angiogenesis, one of the key mechanistic steps for tumor
661 growth, invasion and metastasis in all cell types. Collect-
662 ively, the results point to an interference in metastatic
663 process, revealing potential of A. muricata in prostate
664 cancer treatments.
665 Conclusion
666 The present study is the first demonstration (as far as
667 the authors are aware) of selective, potent cytotoxic ef-
668 fects A. muricata bark extracts, against prostate cancer
669 cell lines (PC3 and DU-145) in comparison with normal
670 cells. Via a panel of in-vitro biochemical probes, the
671 standardized ethyl acetate extract of the bark demon-
672 strated a necrotic path of cell death without inciting re-
673 active oxygen species, inhibiting markers of angiogenesis
674 and enhanced the impact of the chemotherapy docetaxel
675 on DU-145 cells. Taken together, these findings suggest
676 the potential of annonacin and A. muricata bark extract
677 as selective cytotoxic agents with antimetastatic, antian-
678 giogenetic potential and warrants in-vivo investigations
679 to determine physiological measures as well as a
680 complete understanding of the mechanism(s) of the ob-
681 served cytotoxicity.
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